Month: March 2024

2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024 Commercialization Underway with Revenue Expected in 2H 2024 for DeepView AI®-Burn Indication in the UK On Track for Additional Regulatory Submissions in US and UK for DeepView™ System Burn and Diabetic Foot Ulcer Indications DALLAS, March 27, 2024 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities. “Spectral AI achieved much in 2023, and our progress along multiple fronts has...

Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of small oligonucleotides with biological activity and (b) the dramatically improved safety of LNC-docetaxel over IV-docetaxel, with similar efficacy, supports the future use of the LNC platform in inflammation and oncology Conference call begins at 4:30 p.m. Eastern time today BEDMINSTER, N.J., March 27, 2024 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical...

~ Full Year 2023 Revenue Increased 106% to $81.0 Million ~ ~ Fourth Quarter Average Monthly Active Users Sequentially Increased 16% to 67 Million ~ ~ Achieved Company’s Largest Milestone To-Date with Public Launch of Rumble Cloud ~ LONGBOAT KEY, Fla., March 27, 2024 (GLOBE NEWSWIRE) — Rumble Inc. (Nasdaq: RUM) (“Rumble” or the “Company”), the video sharing platform and cloud services provider, today announced financial results for the fiscal quarter and full year ended December 31, 2023. Q4 2023 and Full Year Key HighlightsRevenue for the full year 2023 increased 106% to $81.0 million, compared to $39.4 million for the year ended December 31, 2022. Fourth quarter revenue increased to $20.4 million, compared to $20.0 million in the fourth quarter of 2022, and $18.0 million in the third quarter of 2023. Average...

BOULDER, Colo., March 27, 2024 (GLOBE NEWSWIRE) — Gaia, Inc. (NASDAQ: GAIA) (“Gaia” or the “Company”), a conscious media and community company, reported financial results for the fourth quarter and full year ended December 31, 2023. “We continue to build on Gaia’s increasing momentum. The member count grew to 806,000 at the end of the year and we expect to finish the first quarter of 2024 at about 838,000, a good milestone toward our 15% revenue growth target for 2024,” said Jirka Rysavy, Gaia’s Chairman. “The growth in gross profit per employee was the main driver of our significant cashflow improvement.” Gaia CFO Ned Preston commented: “During 2023, the company generated improvement of $4.2 million in operating cash flow and $8.4 million in free cash flow, with our significant increase in annualized gross profit per employee...

RENO, Nev., March 27, 2024 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable lithium-ion battery recycling, today reported financial results for the full-year ended December 31, 2023. Full-Year 2023 Financial and Recent Operational Highlights OperationalEstablished a platform for commercial production by successfully commissioning the Li AquaRefining™ pilot plant and operating the plant for over one year including 24-hour/five-day per week operations at the Company’s Innovation Center, with the recovery of lithium hydroxide and carbonate, nickel, copper, cobalt, and manganese dioxide, and de-risking through pilot operations. Completed an engineering report that included a Life Cycle Analysis (LCA) of Li AquaRefining™ through ICF, an internationally recognized third party, showing an 83%...

CERRITOS, Calif., March 27, 2024 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2023. Recent Operational HighlightsRemediated material weakness in Internal Controls over review of Complex Accounting Transactions. Signed full-risk capitated contract in South Florida, effective January 1, 2024 and have now successfully onboarded the membership and the IPA providers. Acquired and launched our California-based pharmacy in December and have already completed over 1,300 specialty medication fills. Jeremy Castle enjoyed his first full quarter as our new Chief Operating Officer. Hired 7 new providers in the quarter and ended the year...

Q4 Revenue of $39.4 Million, Net Loss of $3.8 Million & Adjusted EBITDA of $1.1 Million Amends Credit Facility to Eliminate Total Net Leverage Covenant Until Q2 2026 Company to Hold Question-and-Answer Session at 4:30 pm ET Today LOS ANGELES, March 27, 2024 (GLOBE NEWSWIRE) — PLBY Group, Inc. (NASDAQ: PLBY) (“PLBY Group” or the “Company”), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, today provided financial results for the fourth quarter and full year ended December 31, 2023. Comments from Ben Kohn, Chief Executive Officer of PLBY Group “In 2023, we worked on five main goals. First, restructure the Company and move to a capital-light business model; second, reduce overhead; third, stabilize and reposition Honey Birdette back to a premium...

Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions for alvelestat progressing with plans to initiate Phase 3 with a partner around the end of 2024 Cash of $57.4 million as of December 31, 2023 expected to fund operations into 2026 LONDON, March 27, 2024 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2023, and provided an update on recent corporate highlights. “We reached a number of important milestones in 2023, which have set the stage for a potentially transformative 2024,” said...

Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of December 31, 2023 Erasca to host R&D update conference call and webcast Thursday, March 28, 2024 at 8:30 am ET SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal...